Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis

Table 3 Therapeutic regimen and best response in patients after propensity score matching, n (%)

Characteristics	Total (n = 93)	Patients with OBBT (n = 32)	Patients without OBBT (n = 61)	P value
Therapeutic regimen
Chemotriplet regimen	36 (38.7)	6 (18.8)	30 (49.2)	0.006
1Chemodoublet-based regimen	54 (58.1)	24 (75.0)	30 (49.2)
2Monotherapy	3 (3.2)	2 (6.3)	1 (1.6)
Radiographic best response
CR or PR	21 (22.6)	11 (34.4)	10 (16.4)	0.157
SD/no CR or no PR	62 (66.7)	18 (56.2)	44 (72.1)
PD	7 (7.5)	3 (9.4)	4 (6.6)
NA	3 (3.2)	0	3 (4.9)
Radical surgery after systematic treatment
Yes	14 (15.1)	5 (15.6)	9 (14.8)	0.911
No	79 (84.9)	27 (84.4)	52 (85.2)

¹Regimen included a chemodoublet regimen, a chemodoublet plus targeted therapy regimen, and a chemodoublet plus immune checkpoints inhibitor regimen.

²Fluorouracil monotherapy or immune check points inhibitor monotherapy.

OBBT: Overt bleeding before treatment; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NA: Not available.